Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2021-11-04 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2021-11-04 English
BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
Regulatory Filings Classification · 95% confidence The document explicitly identifies itself as a "FORM 6-K" filed with the "SECURITIES AND EXCHANGE COMMISSION" for a "REPORT OF FOREIGN PRIVATE ISSUER". Form 6-K is used by foreign private issuers to report material information not required to be reported on a schedule 13D or 13G, or Form 20-F or 40-F. This filing is typically used to disseminate press releases or other material news to the public in the US market, often mirroring filings made on home exchanges. The content is a press release announcing presentations at the ASH Annual Meeting, which is material information. Since Form 6-K is a general reporting mechanism for foreign private issuers that doesn't fit the specific US domestic forms (like 10-K, 8-K, etc.), and it is a regulatory filing containing material news, the most appropriate classification among the provided options is the general regulatory filing fallback, RNS (Regulatory Filings), as it is not a specific report type like 10-K, ER, or IR, but rather a submission mechanism for material news.
2021-11-04 English
BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The content announces that BioLineRx will have presentations at the 63rd ASH Annual Meeting. Crucially, the text states, 'Attached hereto is a report on*BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition* *Form_6-K_Nov-2021_isa.pdf*'. Since the document itself is a short announcement stating that a report (likely a Form 6-K, which is a general reporting requirement for foreign private issuers) is attached or published, it fits the definition of a Report Publication Announcement (RPA). It is not the full presentation or the detailed financial report itself.
2021-11-04 English
Immediate Report of Meeting to be held on December 2,2021,Proxy
AGM Information Classification · 99% confidence The document is explicitly titled 'NOTICE OF 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS' and contains details about the date (December 2, 2021), agenda items (re-election of directors, reappointment of auditors), voting procedures, and proxy solicitation. This content directly corresponds to the materials distributed for an Annual General Meeting (AGM). Although it mentions reviewing the Annual Report, the primary purpose and structure of the document is the notice and proxy solicitation for the meeting itself. Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-10-28 English
Immediate Report of Meeting to be held on December 2,2021,Proxy
AGM Information Classification · 98% confidence The document explicitly states it is a notice of 'convening of meeting' for an 'annual meeting' scheduled for 02/12/2021. It details the agenda items, which primarily concern the re-election of directors and the reappointment of auditors. This content is characteristic of materials related to an Annual General Meeting (AGM). Although it mentions the attachment of a proxy document ('Proxy_Oct-2021_isa.pdf'), the primary purpose of this filing is the formal announcement and scheduling of the AGM itself, making 'AGM-R' the most appropriate classification over a general 'PSI' or 'RPA'.
2021-10-28 English
6-K
Regulatory Filings
2021-10-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.